Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
about
Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitorsDual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial.An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.Anti-VEGF therapies in the clinicPhase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancerIn pursuit of new anti-angiogenic therapies for cancer treatmentPharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.Novel anti-angiogenic therapeutic strategies in colorectal cancer.Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.
P2860
Q27693185-F9D37AE9-4455-4093-8356-C3325AABBA35Q33414769-4ADCF964-2F35-4243-9B37-6B371E36ED0FQ33684042-D22BF5CA-4241-4903-9D7D-EECF3D0E5D54Q34026037-45A61519-4C82-49DC-8CFA-C6378F2893CFQ34468729-27E79152-A916-4745-A745-0BF1DE3052D3Q34488671-E622E005-5A81-481C-98C9-70F630653253Q34514973-A9BE2359-1073-4970-B0B2-BA347C3F24C1Q34803030-0490446F-9535-4991-8761-3667D9CC90FEQ34854658-C8C07F45-76F8-4FC3-9C61-9B2102CAC680Q35078518-B54E7088-ADB2-48CB-BF62-F5A1551ED88CQ35996229-AACF2116-D27B-478D-A16E-26661072C48AQ36330281-D1716C84-41E7-49A1-8048-13678A68A5BAQ36337646-737A2B8C-F5D5-4AB9-A405-35CADB67108BQ36671812-949234F8-B0B1-4017-AEB1-FD569CC78AC4Q37825180-B2B05DA5-8D1C-41A8-BDE3-622F804CC0CBQ38552109-5A69BC31-39A1-4E7F-9090-B35692AAC94DQ38759141-CB936FCA-4ADD-4108-AB70-7E814D3E33F3Q39036230-E63B3CE0-8772-4C53-9A08-78F114E6444AQ39090350-F7000A91-BFA3-43A8-BC51-AEDF49E43CA8Q45910301-383712CF-0346-4A6B-BB7B-ABBC3BA9E43DQ46648918-F65887D8-F5CE-4FD9-8E56-9EBC02CA5E9CQ48352556-A70B2089-9A53-4EF7-90A3-20B7FA11BD80Q50885562-9DABA54B-3F7C-4544-A1E9-CBCBE557CE5D
P2860
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase I, dose escalation and p ...... ts with advanced solid tumors.
@ast
Phase I, dose escalation and p ...... ts with advanced solid tumors.
@en
type
label
Phase I, dose escalation and p ...... ts with advanced solid tumors.
@ast
Phase I, dose escalation and p ...... ts with advanced solid tumors.
@en
prefLabel
Phase I, dose escalation and p ...... ts with advanced solid tumors.
@ast
Phase I, dose escalation and p ...... ts with advanced solid tumors.
@en
P2093
P1476
Phase I, dose escalation and p ...... nts with advanced solid tumors
@en
P2093
Eisei Shin
Haruyasu Murakami
Hiroshi Nokihara
Kazuhiko Yamada
Kentaro Yamazaki
Narikazu Boku
Noboru Yamamoto
Nobuyuki Yamamoto
Thomas A Puchalski
Tomohide Tamura
P2888
P304
P356
10.1007/S00280-009-0979-8
P577
2009-03-24T00:00:00Z
P6179
1019049611